Researchers compared weight-loss outcomes among midlife women taking two classes of GLP-1–based therapies: semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Zepbound and Mounjaro). The analysis focused on adults over age 45 who were managing overweight or obesity with one of these agents. The study authors drew on electronic health records and other real-world clinical data to assess differences in weight trajectories when menopausal hormone therapy (MHT) was used concurrently. The report was presented at The Menopause Society’s 2026 Annual Conference and has not yet undergone peer review.
About 2,400 women formed the analytic cohort, according to the investigators. Some participants were receiving MHT while others were not. The study team characterized this as the largest comparison to date, in real-world clinical practice, of weight-loss outcomes for semaglutide versus tirzepatide among midlife women with and without MHT. The authors emphasized that their dataset reflects routine-care settings rather than a randomized, controlled trial environment. The source did not report randomized allocation, exact inclusion criteria, dosing regimens, treatment durations, or detailed demographic breakdowns in the summary presented.
Investigators reported that concomitant MHT was associated with a significantly greater and sustained reduction in weight among participants using semaglutide. The lead author, Regina Castaneda, MD, described the finding as encouraging but framed it as hypothesis-generating rather than definitive proof of causation. The study team noted that MHT should not be prescribed solely to enhance weight-loss outcomes; instead, MHT has established clinical indications such as treating bothersome menopausal symptoms. Castaneda also suggested that by relieving vasomotor and other menopausal symptoms, MHT may help some women engage more consistently with diet and physical activity, which are important contributors to sustained weight loss.
When investigators examined outcomes for women taking tirzepatide, the initial data showed a greater weight loss among those also on MHT, but the end-of-study comparisons did not reach statistical significance. The authors offered two possible explanations in their presentation. One explanation cited was a potential “ceiling effect,” given tirzepatide’s relatively large observed weight-loss effect in clinical practice. The source did not provide the complete elaboration of the second explanation in the conference summary available to Medical News Today, and it did not include protocol details that would allow independent assessment of interaction effects between MHT and tirzepatide.
The investigators and quoted experts reiterated that menopause commonly coincides with weight gain, muscle loss, and shifts toward visceral fat as estrogen levels decline. Current options for managing menopausal weight gain include lifestyle interventions, MHT for appropriate menopausal indications, and prescription agents such as GLP-1 receptor agonists. The study authors stressed that MHT has specific therapeutic indications—primarily symptom relief—and that weight management is not an approved primary indication for hormone therapy. They advised clinicians and patients to consider the full clinical picture when discussing combined use of MHT and GLP-1–based medications.
The report is based on observational, real-world clinical data presented at a scientific meeting; it has not been peer reviewed at the time of reporting. The source did not supply key methodological details in the article summary—such as precise dosing, treatment duration, baseline characteristics, adjustment covariates, or safety outcomes—so readers cannot assess causality or safety from this report alone. Investigators called the results hypothesis-generating and implied that randomized, controlled trials or fully reported observational analyses are needed to confirm whether concurrent MHT modulates weight-loss responses to semaglutide or tirzepatide.
The presentation raised specific unanswered questions: Which hormone formulations, routes, and doses—if any—interact with GLP-1 therapies? Do effects differ by timing of initiation, duration of MHT, or baseline symptom burden? The source did not report detail on these points. Finally, because the findings originate from a conference abstract, clinicians should await full peer-reviewed publication before changing prescribing practice or recommending MHT for weight outcomes alone.